Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328605 | 0.95 | MEN1 (0.48) | MEN1KMT2ATDP1ELANETP53 | |
| SCHEMBL10328548 | 0.94 | MEN1 (0.50) | MEN1KMT2ATDP1ELANETP53 | |
| SCHEMBL10494168 | 0.94 | MEN1 (0.50) | MEN1KMT2ATDP1ELANETP53 | |
| SCHEMBL10328642 | 0.85 | PTGER4 (0.37) | MEN1KMT2ATDP1PDE5AELANE | |
| SCHEMBL10328638 | 0.83 | PTGER4 (0.38) | MEN1KMT2ATDP1PDE5AELANE | |
| SCHEMBL6402963 | 0.83 | MRGPRX4 (0.48) | MEN1KMT2ATDP1PTGER4TSHR | |
| SCHEMBL6396266 | 0.81 | LTB4R (0.51) | PDE5A | |
| Water SCHEMBL10548806 | 0.80 | LTB4R (0.50) | PDE5A | |
| SCHEMBL10328645 | 0.80 | LMNA (0.43) | TDP1TP53PTGER4TSHRGPR35 | |
| SCHEMBL6400666 | 0.80 | SMN1; SMN2 (0.44) | MEN1KMT2APTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399651-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | Merck, Sharp & Dohme Corp. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150299227-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2646436-B1 | MONOBACTAMS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| US-9024032-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130084346-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-04-04 | — | — | US | disclosed |
| US-8318945-B2 | Metalloprotein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2120923-B1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI SA (FR) | 2012-07-18 | — | — | EP | disclosed |
| US-20100173952-A1 | METALLOPROTEIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-7705164-B2 | Metalloprotein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090286987-A1 | METALLOPROTEIN INHIBITORS | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO UCSD TECHNOLOGY TRANSFER OFFICE (US) | 2009-11-19 | — | — | US | disclosed |
| US-7579486-B2 | Metalloprotein inhibitors | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2009-08-25 | — | — | US | disclosed |
| WO-2008086949-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | WO | disclosed |
| US-20080161362-A1 | Metalloprotein Inhibitors | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO UCSD TECHNOLOGY TRANSFER OFFICE (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070117848-A1 | METALLOPROTEIN INHIBITORS | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO | 2007-05-24 | — | — | US | disclosed |
| WO-2006028523-A2 | HYDROXYPYRIDINONE, HYDROXYPYRIDINETHIONE, PYRONE, AND THIOPYRONE METALLOPROTEIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286987-A1 | METALLOPROTEIN INHIBITORS | SOD1, ZFX, SOD3 | MEN1 1721/4885KMT2A 1541/4885TDP1 2322/4885 |
| US-20080161362-A1 | Metalloprotein Inhibitors | SOD1, ZFX, SOD3 | MEN1 1721/4885KMT2A 1541/4885TDP1 2322/4885 |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | PC, PCK1, PDK4 | MEN1 1407/4885KMT2A 3575/4885TDP1 4200/4885 |
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | MEN1 2023/4885KMT2A 608/4885TDP1 4806/4885 |
| US-20150299227-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | MEN1 4425/4885KMT2A 317/4885TDP1 479/4885 |
| US-20100173952-A1 | METALLOPROTEIN INHIBITORS | SOD1, ZFX, SOD3 | MEN1 1721/4885KMT2A 1541/4885TDP1 2322/4885 |
| US-20070117848-A1 | METALLOPROTEIN INHIBITORS | SOD1, ZFX, SOD3 | MEN1 1721/4885KMT2A 1541/4885TDP1 2322/4885 |
| US-20130084346-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | MEN1 4425/4885KMT2A 317/4885TDP1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.